|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience显示文摘AIM To evaluate the long-term treatment outcomes of tenofovir therapy in patients in a real world Australian tertiary care setting.METHODS We performed a retrospective analysis of treatment outcomes among treatment-na?ve and treatment-experienced patients receiving a minimum 3 mo tenofovir therapy through St Vincent's Hospital Melbourne, Australia. We included patients receiving tenofovir [tenofovir disoproxil fumarate(TDF)] monotherapy, as well as patients treated with TDF in combination with a second antiviral agent. Patients were excluded if they demonstrated human immune-deficiency virus/hepatitis C virus/hepatitis delta virus coinfection or were less than 18 years of age. We considered virological and biochemicalresponse, as well as safety outcomes. Virological response was determined by measurement of hepatitis B virus(HBV) DNA using sensitive assays; biochemical response was determined via serum liver function tests; histological response was determined from liver biopsy and fibroscan; safety analysis focused on glomerular renal function and bone mineral density. The primary efficacy endpoint was complete virological suppression over time, defined by HBV DNA < 20 IU/m L. Secondary efficacy endpoints included rates of biochemical response, and HB e antigen(HBe Ag)/HB surface antigen loss and seroconversion over time.RESULTS Ninety-two patients were identified who fulfilled the enrolment criteria. Median follow-up was 26 mo(range 3-114). Mean age was 46(24-78) years, 64(70%) were male and 77(84%) were of Asian origin. 55(60%) patients were treatment-na?ve and 62 patients(67%) were HBe Ag-negative. Complete virological suppression was achieved by 45/65(71%) patients at 12 mo, 37/46(80%) at 24 mo and 25/28(89%) at 36 mo. Partial virological response(HBV DNA 20-2000 IU/m L) was achieved by 89/92(96.7%) of patients. Multivariate analysis showed a significant relationship between virological suppression at end of follow-up and baseline HBV DNA level(OR = 0.897, 95%CI: 0.833-0.967, P = 0.0046) and HBe Ag positive status(OR = 0.373, 95%CI: 0.183-0.762, P = 0.0069). There was no difference in response comparing treatment-na?ve and treatment-experienced patients. Three episodes of virological breakthrough occurred in the setting of noncompliance. Tenofovir therapy was well tolerated.CONCLUSION Tenofovir is an efficacious, safe and well-tolerated treatment in an Australian real-world tertiary care setting. Our data are similar to the reported experience from registration trials. | Grace C Lovett Tin Nguyen David M Iser Jacinta A Holmes Robert Chen Barbara Demediuk Gideon Shaw Sally J Bell Paul V Desmond Alexander J Thompson | 2017 | World Journal of Hepatology2017，9，1： | 7 |
| 2 | Human immunodeficiency virus infection and the liver显示文摘Liver disease in human immunodeficiency virus(HIV)-infected individuals encompasses the spectrum from abnormal liver function tests,liver decompensation,with and without evidence of cirrhosis on biopsy,to non-alcoholic liver disease and its more severe form,non-alcoholic steatohepatitis and hepatocellular cancer.HIV can infect multiple cells in the liver,leading to enhanced intrahepatic apoptosis,activation and fibrosis.HIV can also alter gastro-intestinal tract permeability,leading to increased levels of circulating lipopolysaccharide that may have an impact on liver function.This review focuses on recent changes in the epidemiology,pathogenesis and clinical presentation of liver disease in HIV-infected patients,in the absence of co-infection with hepatitis B virus or hepatitis C virus,with a specific focus on issues relevant to low and middle income countries. | Megan Crane David Iser Sharon R Lewin | 2012 | World Journal of Hepatology2012，4，3： | 5 |
| 3 | IL 28 B genotype is not useful for predicting treatment outcome in A sian chronic hepatitis B patients treated with pegylated interferon‐α显示文摘 | Jacinta A Holmes Tin Nguyen Dilip Ratnam Neel M Heerasing Jane V Tehan Sara Bonanzinga Anouk Dev Sally Bell Stephen Pianko Robert Chen Kumar Visvanathan Rachel Hammond David Iser Ferry Rusli William Sievert Paul V Desmond D Scott Bowden Alexander J Thomps | 2013 | J Gastroenterol Hepatol2013，，5： | 2 |
| 4 | The child's experience of ADHD显示文摘 | Sciberras E Efron D Iser A | 2011 | J At-ten Disord2011，15，4： | 1 |
| 5 | Influenza like illness monitoring in adults of the State Capitals and Federal District in Brazil by tele- phone survey 显示文摘 | Reis PO Iser BP Souzal LR | 2011 | Rev2011，，： | 1 |
| 6 | Sofosbuvir plus riba- virin for treatment of hepatitis C virus in patients co-in- fected with HIV (PHOTON-2) : a multicentre, open-label, non-randomised, phase 3 study显示文摘 | Molina JM Orkin C Iser DM | 2015 | Lancet2015，385，9973： | 1 |
| 7 | Reliability and Validity of the Functional Analysis Screening Tool 显示文摘 | lwata Brian A Deleon Iser G Roscoe Eileen M | 2013 | Journal of Applied Behavior Analysis2013，，46： | 1 |
| 8 | Albuminuria in Austral-ian Aboriginal people:prevalence and associations with com-ponents of the metabolic syndrome显示文摘 | Rowley KG Iser DM Best JD | 2000 | Diabetologia2000，43，11： | 1 |
| 9 | Serum hepatitis B surface antigen and hepatits B e angtigen titers:disease phase influences correlation with viral load and intrahepatic hepatitis B vierus markers显示文摘 | Thompson AJ Nguyen T Iser D | 2010 | Hepatology2010，51，： | 1 |
| 10 | Uncoupling protein homologs may provide a link between mitochondria, metabolism and lifespan显示文摘 | Wolkow C A Iser W B | 2006 | Ageing Res Rev2006，5，： | 1 |
| 11 | Serum hepatitis B surface antigen and hepatitis B e antigen titers:dis ease phase influences correlation with viral load and intrahepatic hepatitis B virus mark-ers显示文摘 | Thompson AJ Nguyen T Iser D | | 0，，6： | 1 |
| 12 | The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth显示文摘 | Jana Divisova Isere Kuiatse ZaWaunyka Lazard Heidi Weiss Franzanne Vreeland Darryl L. Hadsell Rachel Schiff C. Kent Osborne Adrian V. Lee | 2006 | Breast Cancer Research and Treatment2006，，3： | 1 |
| 13 | Mesenchymal stem ceils from different murine tissues have differential capacity to metabolize extracellular nucleotides显示文摘 | Iser IC Bracco PA Goncalves CE | 2014 | J Cell Biochem2014，115，10： | 1 |
| 14 | Case report Trichophyton verrucosum infection after needlestick injury with an attenuated live vaccine against cattle ringworm显示文摘 | Seyfarth F Roediger C Gr/iser Y | 2011 | Mycoses2011，54，6： | 1 |
| 15 | Serum hepatitis B surface anti- gen and hepatitis B e antigen titers:disease phase influences correlation with viral load and intrahepatic 显示文摘 | Thompson A J Nguyen T Iser D | 2010 | Hepatology2010，51，6： | 1 |
| 16 | Serum hepatitis B surface B antigen and hepatitis Be antigen titers:disease phase influences correlation with viral load and intrahepatic hepatitis B virus marker 显示文摘 | Thompson A J Nguyen T Iser D | 2010 | Hepatology2010，51，6： | 1 |
| 17 | Serum hepatitis B surface antigen and hepatitis B e antigen titers:disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers显示文摘 | Thompson AJ Nguyen T Iser D | 2010 | Hepatology2010，51，6： | 1 |
| 18 | Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahe- patic hepatitis B virus markers 显示文摘 | Thompson A J Nguyen T Iser D | 2010 | Hepatology2010，51，6： | 1 |
| 19 | Serum hepatitis B sur- face antigen and hepatitis B e antigen titers, disease phase in- fluences correlation with viral Foad and intrahepatic He - patitis B virus markers显示文摘 | Alexander JV Nguyen l-r Iser D | 2010 | Hepatology2010，51，6： | 1 |
| 20 | The new species concept in demato- phytes-a polyphasic approach 显示文摘 | Gr~iser Y Soott J Summerbell R | 2008 | Mycopathologia2008，166，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员